Zacks Investment Research upgraded shares of OptiNose (NASDAQ:OPTN) from a sell rating to a hold rating in a research note published on Wednesday.
According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company’s lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. “
Separately, ValuEngine raised shares of OptiNose from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $29.25.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Monday, May 14th. The company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.07). The firm had revenue of $0.87 million for the quarter. equities research analysts expect that OptiNose will post -3.26 EPS for the current year.
In related news, CEO Peter K. Miller purchased 5,054 shares of the firm’s stock in a transaction dated Friday, March 16th. The stock was purchased at an average price of $18.58 per share, with a total value of $93,903.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 67.80% of the company’s stock.
A number of hedge funds have recently modified their holdings of OPTN. Schwab Charles Investment Management Inc. purchased a new position in OptiNose during the fourth quarter valued at approximately $432,000. Peregrine Capital Management LLC purchased a new position in OptiNose during the fourth quarter valued at approximately $6,314,000. Kornitzer Capital Management Inc. KS purchased a new position in OptiNose during the fourth quarter valued at approximately $6,040,000. American Century Companies Inc. purchased a new position in OptiNose during the fourth quarter valued at approximately $1,745,000. Finally, Wells Fargo & Company MN purchased a new position in OptiNose during the fourth quarter valued at approximately $5,392,000. 29.86% of the stock is currently owned by institutional investors.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.